AUAUniversity Podcast Series: Episode No. 9

AUA2019 077IC Establishing A Multidisciplinary Oncology Clinic With Advanced Therapeutics

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme

本课程将提供一个框架，以建立一个多学科的临床治疗泌尿系统恶性肿瘤，代表泌尿科医生，医学肿瘤学家和其他专家一起工作，以团队为基础的方法。该课程将重点放在整合先进的治疗方法，包括免疫基础治疗，适用于多学科设置。参与者将更好地了解转诊肿瘤医学的最佳时机，具体例子包括激素敏感性转移性前列腺癌，肌肉浸润性膀胱癌的新辅助化疗，免疫治疗在晚期膀胱癌和肾癌中的作用。将讨论将肿瘤基因组特征和个性化医学整合到手术计划、肿瘤活检和化疗免疫治疗选择中。重点将放在即将扩大的检查点抑制剂在泌尿系统恶性肿瘤和改变疾病进展的定义。

Learning Objectives:

• Describe the components of a multidisciplinary urologic cancer cancer and identify the best structure for the practice.
• Deliver advanced therapeutics based on current and emerging best evidence including immunotherapy in urologic oncology patients
• Identify opportunities for shared care and team-based approaches of patients with urologic cancers including advanced prostate, bladder, and kidney cancer.
• Demonstrate an understanding of advances in genomic testing and personalized medicine for urologic cancers.
• Differentiate between new therapeutics that expand the treatment options for patients with urologic cancers and alter the definitions of cancer treatment.